AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 430
- Registration Number
- NCT06599502
- Locations
- 🇹🇷
Research Site, Istanbul, Turkey
A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 408
- Registration Number
- NCT06602479
- Locations
- 🇪🇸
Research Site, Valencia, Spain
A Study in Participants With Obesity or Overweight With at Least One Weight-related Comorbidity
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 231
- Registration Number
- NCT06595238
- Locations
- 🇬🇧
Research Site, Rotherham, United Kingdom
Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 16
- Registration Number
- NCT06594068
- Locations
- 🇺🇸
Research Site, Las Vegas, Nevada, United States
A Phase I Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD0780
- First Posted Date
- 2024-09-12
- Last Posted Date
- 2024-09-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 42
- Registration Number
- NCT06592482
- Locations
- 🇺🇸
Research Site, Saint Paul, Minnesota, United States
Establish FeNO Cut-off Value for Predicting Budesonide-formoterol Response in Chronic Cough Suggestive of CVA Patients.
Not Applicable
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-09-11
- Last Posted Date
- 2024-09-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1000
- Registration Number
- NCT06590740
- Locations
- 🇨🇳
Research Site, Guangzhou, China
Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-08-30
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 384
- Registration Number
- NCT06579105
- Locations
- 🇬🇧
Research Site, Dundee, United Kingdom
Effects of AZD5004 in Adults Who Are Living With Obesity or Overweight With at Least 1 Weight-related Comorbidity
- First Posted Date
- 2024-08-30
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 304
- Registration Number
- NCT06579092
- Locations
- 🇬🇧
Research Site, Witney, United Kingdom
Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD0780
- First Posted Date
- 2024-08-29
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 32
- Registration Number
- NCT06576765
- Locations
- 🇺🇸
Research Site, San Antonio, Texas, United States
A Multifaceted Intervention to Improve Bleeding Management Among Patients Using Oral Anticoagulants (IMPACT-BLEEDING)
Not yet recruiting
- Conditions
- First Posted Date
- 2024-08-28
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 168
- Registration Number
- NCT06575517
© Copyright 2024. All Rights Reserved by MedPath